{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:45Z","timestamp":1790916825520,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":188,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101320","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:46:00Z","timestamp":1783770360000},"page":"101320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immune Checkpoint Inhibitor Outcomes Across Child-Pugh A, B, and C Hepatocellular Carcinoma: A Real-World Integrated Health-System Cohort"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2148-4425","authenticated-orcid":false,"given":"Alireza","family":"Tojjari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stela","family":"Celaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Biggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-9401","authenticated-orcid":false,"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101320_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101320_bib0002","doi-asserted-by":"crossref","DOI":"10.1007\/s10555-026-10327-0","article-title":"Hyponatremia in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-014 meta-analysis","volume":"45","author":"Vitale","year":"2026","journal-title":"Cancer Metastasis Rev."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101320_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011091","article-title":"Hepatocellular carcinoma immunotherapy: predictors of response, issues, and challenges","volume":"25","author":"Rizzo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101320_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70132","article-title":"Metabolic dysfunction-associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: a deadly triad","volume":"56","author":"Caturano","year":"2026","journal-title":"Eur. J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101320_bib0005","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3390\/jpm12111788","article-title":"Trans-arterial chemoembolization plus systemic treatments for hepatocellular carcinoma: an update","volume":"12","author":"Rizzo","year":"2022","journal-title":"J. Pers. Med."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101320_bib0006","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2217\/fon-2021-1623","article-title":"Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101320_bib0007","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101320_bib0008","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1097\/CM9.0000000000003264","article-title":"Global epidemiology of liver cancer 2022: an emphasis on geographic disparities","volume":"137","author":"Li","year":"2024","journal-title":"Chin. Med. J. (Engl)"},{"issue":"20","key":"10.1016\/j.ctarc.2026.101320_bib0009","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101320_bib0010","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101320_bib0011","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM. Evid."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101320_bib0012","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101320_bib0013","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"83","author":"Rimassa","year":"2025","journal-title":"J. Hepatol."},{"issue":"27","key":"10.1016\/j.ctarc.2026.101320_bib0014","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of Tremelimumab Plus Durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10408","key":"10.1016\/j.ctarc.2026.101320_bib0015","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"10492","key":"10.1016\/j.ctarc.2026.101320_bib0016","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"10088","key":"10.1016\/j.ctarc.2026.101320_bib0017","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101320_bib0018","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101320_bib0019","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/jamaoncol.2023.3284","article-title":"Immune checkpoint inhibitors for child-pugh class B advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"9","author":"Xie","year":"2023","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101320_bib0020","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jamaoncol.2024.2166","article-title":"Immunotherapy vs best supportive care for patients with hepatocellular cancer with Child-Pugh B dysfunction","volume":"10","author":"Fulgenzi","year":"2024","journal-title":"JAMa Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101320_bib0021","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101320_bib0022","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101320_bib0023","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","article-title":"Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment","volume":"81","author":"Celsa","year":"2025","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101320_bib0024","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1158\/1078-0432.CCR-24-2582","article-title":"Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab or sorafenib at highest risk of death","volume":"31","author":"Cabibbo","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101320_bib0025","first-page":"397","article-title":"Treatment-related decompensation in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"79","author":"D'Alessio","year":"2024","journal-title":"Hepatology"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2026.101320_bib0026","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e16184","article-title":"Nivolumab\/pembrolizumab in Child-Pugh grade B\/C patients with advanced HCC","volume":"39","author":"Wong","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101320_bib0027","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101320_bib0028","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101320_bib0029","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101320_bib0030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101320_bib0031","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101320_bib0032","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br. J. Surg."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101320_bib0033","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach \u2014 the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.ctarc.2026.101320_bib0034","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101320_bib0035","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101320_bib0036","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"9596","key":"10.1016\/j.ctarc.2026.101320_bib0037","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101320_bib0038","first-page":"225","article-title":"A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma","volume":"12","author":"Wang","year":"2024","journal-title":"J. Transl. Int. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101320_bib0039","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000535839","article-title":"Analysis of immune-related adverse events of atezolizumab and bevacizumab in patients with hepatocellular carcinoma: a multicentre cohort study","volume":"13","author":"Nam","year":"2024","journal-title":"Liver. Cancer"},{"key":"10.1016\/j.ctarc.2026.101320_bib0040","article-title":"Immune-mediated adverse events and overall survival with Tremelimumab plus Durvalumab and Durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA Phase III randomized clinical trial","author":"Lau","year":"2025","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101320_bib0041","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2023.10.040","article-title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","volume":"80","author":"Celsa","year":"2024","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101320_bib0042","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/oncolo\/oyae142","article-title":"Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study","volume":"29","author":"Storandt","year":"2024","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101320_bib0043","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3390\/cancers14071722","article-title":"Efficacy and safety of Atezolizumab and Bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: experience from four tertiary centers","volume":"14","author":"Himmelsbach","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101320_bib0044","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study","volume":"76","author":"D'Alessio","year":"2022","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101320_bib0045","article-title":"Efficacy and safety of Atezolizumab plus Bevacizumab for patients with hepatocellular carcinoma and Child-Pugh class B","volume":"45","author":"Sasaki","year":"2025","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101320_bib0046","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000452846","article-title":"Albumin\u2013bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications","volume":"6","author":"Hiraoka","year":"2017","journal-title":"Liver. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101320_bib0047","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"Pinato","year":"2017","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101320_bib0048","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/liv.15502","article-title":"Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: an international observational study","volume":"43","author":"Talbot","year":"2023","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101320_bib0049","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","article-title":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy\u2013development and validation of the CRAFITY score","volume":"76","author":"Scheiner","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101320_bib0050","first-page":"231","article-title":"Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis","volume":"23","author":"Yang","year":"2023","journal-title":"BMC. Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101320_bib0051","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/liv.14223","article-title":"Biology and significance of alpha-fetoprotein in hepatocellular carcinoma","volume":"39","author":"Galle","year":"2019","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101320_bib0052","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12072-022-10406-8","article-title":"Development and validation of a modified albumin-bilirubin grade and \u03b1-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab","volume":"17","author":"Hatanaka","year":"2023","journal-title":"Hepatol. Int."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101320_bib0053","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000529996","article-title":"Albumin-bilirubin grade analyses of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: a post hoc analysis of the phase III IMbrave150 study","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver. Cancer"},{"issue":"7854","key":"10.1016\/j.ctarc.2026.101320_bib0054","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101320_bib0055","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","article-title":"Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups","volume":"70","author":"Pinter","year":"2021","journal-title":"Gut"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:28Z","timestamp":1790913688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":55,"alternative-id":["S2468294226002315"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101320","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor Outcomes Across Child-Pugh A, B, and C Hepatocellular Carcinoma: A Real-World Integrated Health-System Cohort","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101320"}}